Human genetic markers associated with response to treatments that target clostridium difficile toxin B

US12071666B2 · kind B2 · utility

Assignees

• Merck Sharp & Dohme LLC · US
• Beijing Genomics Institute at Shenzhen · CN

Inventors

• Peter Shaw · Yardley, US
• Devan V. Mehrotra · Lansdale, US
• Rebecca L. Blanchard · Allentown, US
• Judong Shen · Westfield, US
• Robin Mogg · Forest Park, US
• Mary Beth Dorr · Collegeville, US
• Junhua Li · Shanghai, CN
• Xun Xu · Shanghai, CN

Key dates

• Filing date: Dec 7, 2017
• Grant date: Aug 27, 2024
• Expiry date: Feb 25, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/156
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides genetic markers on human chromosome 6 that are associated with a beneficial response to a treatment that targets Clostridium difficile (C. difficile) toxin B (TcdB), e.g. a TcdB antibody. These TcdB treatment response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment that targets TcdB in methods of treating patients having a disease susceptible to treatment with a TcdB antibody, and in methods for selecting the most appropriate therapy for such patients. The invention also provides antibodies, drug products, and kits useful with the TcdB Treatment response markers of the invention.